Vacon Plc, Stock Exchange Release, 26 July 2013 at 1.00 pm (EET) Vacon will publish its Interim Report January - June 2013 on Thursday, 1 August, 2013 at around 9.30 am Finnish time. A briefing for the financial analysts and media will be held on the same day at Pörssitalo, Fabianinkatu 14 A, 2nd floor, Helsinki (entrance via NASDAQ OMX Helsinki's reception) at 11:30 am Finnish time (EET). Please inform Maija Suutarinen of your participation at maija.suutarinen(at)vacon.com no later than 29 July, 2013. A dial-in conference for investors and investment analysts will be held at 3.00 pm (EET) on 1 August 2013. President and CEO Vesa Laisi and CFO Pia Aaltonen- Forsell will participate in the conference. Please call +358(0)9 6937 9543 (Finland Toll) or +44(0)20 3427 1909 (UK Toll) and request to be connected to the Vacon call (Confirmation code 9226072). A recording of the conference will be available for seven days at (0)9 2310 1650 (Finland Toll) or (0)20 3427 0598 (UK Toll) and access code 9226072#. Webcast URL: http://www.media-server.com/m/p/5hwz8ohg The presentation material will be available before the start of the briefing at the Vacon's website www.vacon.com > Investors > Publications and releases. VACON PLC Further information: * Sebastian Linko, Director, Corporate Communications and Investor Relations, +358 (0)40 8371 634, sebastian.linko(at)vacon.com Vacon in brief Vacon is driven by a passion to develop, manufacture and sell the best AC drives and inverters in the world - and provide customers with efficient product lifecycle services. Our AC drives offer optimum process control and energy efficiency for electric motors. Vacon inverters play a key role when energy is produced from renewable sources. Vacon has production and R&D facilities in Europe, Asia and North America, and sales offices in 29 countries. Further, Vacon has sales representatives and service partners in nearly 90 countries. In 2012, Vacon's revenues amounted to EUR 388.4 million, and the company employed globally approximately 1,500 people. The shares of Vacon Plc (VAC1V) are quoted on the main list of the Helsinki stock exchange (NASDAQ OMX Helsinki). Driven by Drives, www.vacon.com Distribution: NASDAQ OMX Helsinki Financial Supervisory Authority Main media [HUG#1719060]
Invitation to Vacon's second quarter 2013 results briefing
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Ovation's Roadmap for Revitalizing Rural Healthcare
Steering Rural Healthcare Towards a Brighter Future Alright, here we are with Ovation Healthcare trying to inject some much-needed life into the sometimes forgotten corners of the healthcare world—those rural hospitals. They’ve cooked up a fresh white paper, and it’s got the makings of a lifeline for these institutions swirling in red ink. The financial landscape...
Continue Reading
ProperHeir Expands with New Innovative Office Space
ProperHeir Expands with New Innovative Office Space ProperHeir has recently announced an exciting development with the opening of its new office at the Miramar Tech Center. This expansion marks a significant milestone as the company has tripled its available space. The chief purpose of this new office is to effectively host its growing in-house sales team and provide a...
Continue Reading
Discover How Octa Transforms Forex Trading for Singaporeans
Understanding the Forex Market The foreign exchange market, commonly known as forex, stands as the largest and most dynamic financial market in the world. It allows traders to buy and sell currencies, leveraging the fluctuations in exchange rates to boost their earnings. Operating continuously from Monday to Friday, this market presents individual traders with the chance...
Continue Reading
Seoul Business Agency Powers Startups at the CES 2026 Pavilion
Seoul Business Agency Showcases Startups at CES 2026 Pavilion The Seoul Business Agency (SBA) has taken ambitious strides to support the innovative spirit of Seoul's startups at CES 2026. Engaging with 19 prestigious institutions within Seoul’s ecosystem, the SBA is dedicated to empowering 70 startups as they venture onto the global stage. The 'Seoul POP' themed...
Continue Reading
VYJUVEK® Receives Groundbreaking Approval for DEB Treatment
VYJUVEK® Approved for Dystrophic Epidermolysis Bullosa Treatment VYJUVEK approved for DEB treatment from birth, offering flexible home administration options for patients and their families. This breakthrough marks VYJUVEK as the first genetic medicine approved in Japan for DEB. Recently, Krystal Biotech, Inc. (NASDAQ: KRYS) announced that its innovative treatment,...
Continue Reading